How should a ceftriaxone intradermal skin test be performed and interpreted for accurate assessment?

Ceftriaxone Intradermal Test: Standardized Protocol

For ceftriaxone intradermal skin testing, perform a 3-step protocol starting with epicutaneous (prick/puncture) testing at 100 mg/mL, followed by intradermal testing at 1 mg/mL (Step 2) and 10 mg/mL (Step 3), reading at 20 minutes for immediate hypersensitivity—though evidence shows this testing has extremely limited clinical utility with 0% sensitivity and should primarily be reserved for patients with severe/recurrent reaction histories. 1, 2

Testing Protocol

Step-by-Step Approach

Step 1: Epicutaneous (Prick/Puncture) Test

• Concentration: 100 mg/mL
• Perform on volar forearm
• Read at 20 minutes for immediate reactions 1

Step 2: Intradermal Test (if Step 1 negative)

• Concentration: 1 mg/mL
• Volume: 0.02 mL (standardized volume) 3
• Expected initial wheal diameter: 5 mm (range 2-9 mm) 3
• Recommended primarily for patients with severe/recurrent reaction history 1

Step 3: Intradermal Test (if Step 2 negative)

• Concentration: 10 mg/mL
• Volume: 0.02 mL
• Same technique as Step 2 1

Reading and Interpretation

Timing of readings:

• Immediate hypersensitivity: Read at 20 minutes 1, 4
• Delayed reactions: Additional readings at Day 1, Day 2, Day 4, and 1 week 4

Positive test criteria:

• Wheal diameter increase ≥3 mm compared to negative control at 20 minutes for immediate reactions
• Erythema, induration, or papules at delayed reading times

Critical Clinical Context

Major Limitation: Poor Predictive Value

The most important caveat is that ceftriaxone intradermal testing has extremely poor clinical utility. A prospective study of 1,421 patients demonstrated:

• Sensitivity: 0%
• Specificity: 97.5%
• Positive predictive value: 0%
• Negative predictive value: 99.7% 2

In this study, 74 patients (5.2%) tested positive to at least one cephalosporin, but none developed immediate hypersensitivity reactions upon challenge with the same or different cephalosporin. Conversely, 4 patients who developed generalized urticaria after challenge had negative skin tests 2.

When Testing May Be Considered

Despite poor sensitivity, skin testing may have limited utility in specific scenarios:

Consider testing for:

• Patients with history of anaphylaxis to cephalosporins requiring parenteral cephalosporin with non-identical R1 side chain 1
• Patients with severe and/or recurrent reactions 1
• Patients with multiple drug allergies (possibility of coexisting sensitivities) 1

Do NOT routinely test:

• Patients with unverified penicillin allergy requiring ceftriaxone (cross-reactivity rate only 2.11% for low-similarity cephalosporins like ceftriaxone) 1
• Routine preoperative screening 2

Cross-Reactivity Considerations

Ceftriaxone has low cross-reactivity with penicillins:

• Classified as "low-similarity-score cephalosporin"
• Cross-reactivity rate: 2.11% (95% CI: 0.98-4.46%) in proven penicillin allergy 1
• Shares R1 side chain with amoxicillin/ampicillin and cefotaxime (see structural similarity) 1

Standardized Technique Details

Preparation

• Use sterile injectable form or reconstituted pure drug
• Prepare sequential dilutions in sterile saline
• Most reproducible method: Fill syringe, expel excess to obtain exactly 0.02 mL 3

Injection Technique

• Site: Volar forearm (site does not affect wheal diameter) 3
• Volume: 0.02 mL produces most consistent results
• Inject intradermally to create visible wheal
• Mark injection site for reading

Controls

• Negative control: Saline (0.02 mL)
• Positive control: Histamine (if testing for immediate reactions)
• Essential to avoid false-positive results 4

Post-Test Management

If skin test negative:

• Proceed to drug challenge (1-2 steps) to confirm tolerance 1
• Number of challenge steps determined by: patient allergy history, clinical stability, comorbidities, and R1 side chain similarity 1

If skin test positive:

• Consider desensitization procedure OR
• Use alternative cephalosporin with different R1 side chain (skin test negative) 1

Important Exclusions

Do NOT use this protocol for:

• Severe delayed immunologic reactions (SCARs, SJS/TEN)
• Organ-specific reactions (hemolytic anemia, drug-induced liver injury, acute interstitial nephritis) 1
• These require different evaluation approaches

Timing Considerations

Optimal testing window:

• Perform 6 weeks to 6 months after complete healing of reaction 4
• Time since original reaction inversely predicts positive skin test (adjusted OR per year: 0.71,95% CI: 0.56-0.90) 5

Bottom line: Given the 0% sensitivity and 0% positive predictive value demonstrated in prospective validation studies, routine ceftriaxone intradermal testing before administration is not clinically useful for predicting immediate hypersensitivity 2. When testing is performed in select high-risk patients, follow the standardized 3-step protocol with proper technique and recognize that a negative test requires confirmation with graded drug challenge.